Clinical Trials Browser

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Meningeal Carcinomatosis

NCT06007937 2026-04-08

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

Phase 1/2 Recruiting

56 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Recurrence

NCT06282991 2026-03-10

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Completed

73 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06678555 2026-02-05

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Active not recruiting

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05740943 2026-01-20

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Phase 2 Active not recruiting

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05144997 2025-12-17

Lorlatinib Continuation Study

Phase 4 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03052608 2025-11-25

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Phase 3 Active not recruiting

296 enrolled 28 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03909971 2025-11-05

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Phase 2 Completed

109 enrolled 33 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Phase 2 Not yet recruiting

21 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05834348 2025-03-30

DELINOR

Completed

5,279 enrolled 10 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06876675 2025-03-14

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

Enrolling by invitation

167 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Hyperlipidemias

NCT06690541 2024-11-15

COMLORLA

Not yet recruiting

100 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04127110 2024-11-05

ALKALINE

Phase 2 Active not recruiting

68 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04322890 2024-10-22

PIKACHU

Phase 2 Recruiting

6,000 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04800822 2024-10-22

PF-07284892 in Participants With Advanced Solid Tumors

Phase 1 Terminated

53 enrolled

CNSGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neurofibromatosis 1, Hereditary Sensory and Autonomic Neuropathies, Colorectal Neoplasms

NCT05014464 2024-09-20

ATPase

Phase 2 Recruiting

90 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01970865 2024-08-12

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

Phase 1/2 Completed

364 enrolled 89 charts 2 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03546894 2024-07-15

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

111 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05948462 2023-12-13

NSCLC

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT02584634 2023-07-07

Javelin Lung 101

Phase 1/2 Terminated

43 enrolled 40 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04541407 2023-05-16

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

Phase 1 Completed

1 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05167500 2023-03-30

LORLAPULM

Completed

118 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasm Metastasis

NCT03612154 2022-04-06

Study of Lorlatinib in ROS1 Rearranged NSCLC

Phase 2 Unknown

35 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03439215 2021-07-19

PFROST

Phase 2 Unknown

20 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02927340 2021-03-09

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions

Phase 2 Unknown

30 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Clinical Trials

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

Lorlatinib Continuation Study

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

DELINOR

LORLATINIB-related HYPERLIPIDEMIA in ALK+ Non-Small Cell Lung Cancer

COMLORLA

ALKALINE

PIKACHU

PF-07284892 in Participants With Advanced Solid Tumors

ATPase

A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations

EROS

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

NSCLC

Javelin Lung 101

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

LORLAPULM

Study of Lorlatinib in ROS1 Rearranged NSCLC

PFROST

A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions